Newsroom | 52384 results
Sorted by: Latest
-
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi...
-
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...
-
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte’s frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival...
-
Das grundlegende hämatologische Produktportfolio von BeOne Medicines läutet auf der EHA 2026 eine neue Ära der Innovation bei B-Zell-Krebserkrankungen ein
SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, präsentierte heute auf dem Kongress der European Hematology Association (EHA) 2026 in Stockholm neue Daten aus seinem grundlegenden hämatologischen Produktportfolio. Aktualisierte Ergebnisse zu Tacabrutideg (BGB-16673), einem möglichen Best-in-Class-Bruton-Tyrosinkinase (BTK)-Degrader, zeigten anhaltende Ansprechraten bei vorbehandelten Patienten mit rezidiv...
-
La línea de productos de hematología de BeOne Medicines marca el rumbo de la próxima era de innovación en el cáncer de células B en la EHA 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa oncológica internacional, anunció el día de hoy nuevos datos acerca de su línea de productos hematológicos en el Congreso de la Asociación Europea de Hematología (EHA, por sus siglas en inglés) de 2026, celebrado en Estocolmo. Los resultados actualizados del tacabrutideg (BGB-16673), un degradador de la tirosina quinasa de Bruton (BTK) que podría ser el mejor de su clase, demostraron r...
-
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test.1 The approval by the US FDA was bas...
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
RAHWAY, N.J.--(BUSINESS WIRE)--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC...
-
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) cov...
-
BeOne präsentiert auf der EHA 2026 wegweisende Daten aus der Phase-3-Studie bei CLL-Patienten im Alter von über 80 Jahren und untermauert damit den Nutzen von BRUKINSA
SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute die Präsentation umfangreicher Phase-3-Daten bei Patienten mit chronischer lymphatischer Leukämie oder kleinem lymphozytischem Lymphom (CLL/SLL) im Alter von 80 Jahren und älter bekannt. Diese zeigen einen anhaltenden Nutzen von BRUKINSA nach fast 6,5 Jahren Nachbeobachtungszeit und untermauern damit dessen Rolle als grundlegender BTK-Inhib...
-
Franquia de hematologia fundamental da BeOne Medicines lidera próxima era da inovação em câncer de células B na EHA 2026
SAN CARLOS, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa multinacional de oncologia, anunciou hoje novos dados de sua principal linha de produtos hematológicos no Congresso da Associação Europeia de Hematologia (EHA) de 2026, em Estocolmo. Os resultados atualizados do tacabrutideg (BGB-16673), um potencial degradador de tirosina quinase de Bruton (BTK) líder de mercado, demonstraram respostas duradouras em pacientes com leucemia linfocít...
